| Basics |
OptiNose, Inc. Common Stock
OptiNose Inc is a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists.
|
| IPO Date: |
October 9, 2017 |
| Sector: |
Healthcare |
| Industry: |
Drug Manufacturers - Specialty and Generic |
| Market Cap: |
$98.13M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.19 | 3.28%
|
| Avg Daily Range (30 D): |
$0.05 | 0.54%
|
| Avg Daily Range (90 D): |
$0.11 | 1.70%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.3M |
| Avg Daily Volume (30 D): |
.04M |
| Avg Daily Volume (90 D): |
.07M |
| Trade Size |
| Avg Trade Size (Sh.): |
169 |
| Avg Trade Size (Sh.) (30 D): |
156 |
| Avg Trade Size (Sh.) (90 D): |
155 |
| Institutional Trades |
| Total Inst.Trades: |
135 |
| Avg Inst. Trade: |
$1.58M |
| Avg Inst. Trade (30 D): |
$3.17M |
| Avg Inst. Trade (90 D): |
$1.46M |
| Avg Inst. Trade Volume: |
.03M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.56M |
| Avg Closing Trade (30 D): |
$3.17M |
| Avg Closing Trade (90 D): |
$3.17M |
| Avg Closing Volume: |
47.62K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$-3.94
|
$-1.92
|
$-1.97
|
|
Diluted EPS
|
$-3.91
|
$-1.92
|
$-1.92
|
|
Revenue
|
$ 81.86M
|
$ 18.51M
|
$ 22.42M
|
|
Gross Profit
|
$ 74.11M
|
$ 16.76M
|
$ 20.47M
|
|
Net Income / Loss
|
$ -29.89M
|
$ -22.42M
|
$ -.36M
|
|
Operating Income / Loss
|
$ -15.84M
|
$ -7.59M
|
$ .36M
|
|
Cost of Revenue
|
$ 7.75M
|
$ 1.75M
|
$ 1.95M
|
|
Net Cash Flow
|
$ 21.29M
|
$ -11.55M
|
$ 1.99M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Dec 31, 2024:
1:15
|
|
|
|
